| LDL Receptor-Related Protein 6 Modulates Ret Proto-Oncogene Signaling in Renal Development and Cystic Dysplasia. | kidney, |
| Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma. | breast, |
| Our results further substantiate that most germline mutations of the RET proto-oncogene were localized at codon 634 in Chinese hereditary medullary thyroid carcinoma patients and carriers | thyroid, |
| Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine. | thyroid, |
| Catecholamine crisis as a first manifestation of familial bilateral pheochromocytoma caused by RET proto-oncogene mutation in codon C 634R. | PCPG, |
| CNTN1 is a new gene which can be regulated by RET/PTC3 (Ret proto-oncogene and Ret-activating protein ELE1) rearrangement gene and the protein level of CNTN1 is increasing in thyroid cancer. | thyroid, |
| RET proto-oncogene mutation is associated with Hereditary Medullary Thyroid Carcinoma. | thyroid, |
| activation of the MAPK and PI3K-AKT pathways primarily regulated Ser-727 phosphorylation, whereas a physical interaction between RET/PTC3 and STAT1, followed by a direct tyrosine phosphorylation event, was necessary for STAT1 Tyr-701 phosphorylation. These data provide the first evidence of a direct link between IDO1 expression and the oncogenic activation of RET in thyroid carcinoma | thyroid, |
| Study identified TP53 and RET among the most mutated oncogenes in hepatocellular carcinoma to be associated with lower overall survival. | liver, |
| RET alterations, such as RET-oncogene fusions, are present in a subset of breast cancers, and are promising therapeutic targets. | breast, |
| an unbalanced cofilin expression, induced by oncogenic RET, contributes to promote Medullary thyroid carcinoma invasiveness and growth. | thyroid, |
| Novel RET Proto-oncogene variants identified in Turkish patients with thyroid carcinoma. | thyroid, |
| [Ret proto-oncogene mutations associated with type 2 multiple endocrine neoplasms (MEN 2). Clinical implications]. | neoplasm, |
| Absence of RET proto-oncogene point mutations in sporadic hyperplastic and neoplastic lesions of the parathyroid gland. | thyroid, |
| Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas. | thyroid, |
| RET/PTC oncogene activation is an early event in thyroid carcinogenesis. | thyroid, |
| RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma. | thyroid, |
| Molecular defects in thyroid carcinomas: role of the RET oncogene in thyroid neoplastic transformation. | thyroid, |
| Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. | thyroid, |
| A single missense mutation in codon 918 of the RET proto-oncogene in sporadic medullary thyroid carcinomas. | thyroid, |